Home

Csodálatra méltó hegy Eredeti z fever kawasaki Gyűrűcske fog dönteni csodál

Refractory Kawasaki disease: diagnostic and management challenges | PHMT
Refractory Kawasaki disease: diagnostic and management challenges | PHMT

Kawasaki Disease
Kawasaki Disease

Kawasaki disease: AHA statement and recommendations
Kawasaki disease: AHA statement and recommendations

Diagnosis and Management of Kawasaki Disease | AAFP
Diagnosis and Management of Kawasaki Disease | AAFP

Diagnosis and Management of Kawasaki Disease | AAFP
Diagnosis and Management of Kawasaki Disease | AAFP

Rheumato | Free Full-Text | Kawasaki Disease: Management Challenges during  COVID-19 Pandemic with an Upsurge in Multisystem Inflammatory Syndrome in  Children
Rheumato | Free Full-Text | Kawasaki Disease: Management Challenges during COVID-19 Pandemic with an Upsurge in Multisystem Inflammatory Syndrome in Children

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A  Scientific Statement for Health Professionals From the Ame
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the Ame

Value of serial echocardiography in diagnosing Kawasaki's disease |  SpringerLink
Value of serial echocardiography in diagnosing Kawasaki's disease | SpringerLink

Kawasaki disease: AHA statement and recommendations
Kawasaki disease: AHA statement and recommendations

Kawasaki Disease | Circulation
Kawasaki Disease | Circulation

An Overview of Kawasaki Disease
An Overview of Kawasaki Disease

Revised recommendations of the Italian Society of Pediatrics about the  general management of Kawasaki disease | Italian Journal of Pediatrics |  Full Text
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text

Rheumato | Free Full-Text | Kawasaki Disease: Management Challenges during  COVID-19 Pandemic with an Upsurge in Multisystem Inflammatory Syndrome in  Children
Rheumato | Free Full-Text | Kawasaki Disease: Management Challenges during COVID-19 Pandemic with an Upsurge in Multisystem Inflammatory Syndrome in Children

RAISE Study: New evidence of Kawasaki disease's treatment
RAISE Study: New evidence of Kawasaki disease's treatment

An Overview of Kawasaki Disease
An Overview of Kawasaki Disease

KAWASAKI DISEASE: WHAT TO DO WITH INCOMPLETE CASES? | ADC Education &  Practice Edition
KAWASAKI DISEASE: WHAT TO DO WITH INCOMPLETE CASES? | ADC Education & Practice Edition

16: Kawasaki Disease with Recrudescent Guest Dr. Tremoulet - The Curbsiders
16: Kawasaki Disease with Recrudescent Guest Dr. Tremoulet - The Curbsiders

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A  Scientific Statement for Health Professionals From the American Heart  Association | Circulation
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation

2021 American College of Rheumatology/Vasculitis Foundation Guideline for  the Management of Kawasaki Disease
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Understanding Kawasaki Disease
Understanding Kawasaki Disease

Multisystem inflammatory syndrome (MIS-C) in Pakistani children: A  description of the phenotypes and comparison with historical cohorts of  children with Kawasaki disease and myocarditis | PLOS ONE
Multisystem inflammatory syndrome (MIS-C) in Pakistani children: A description of the phenotypes and comparison with historical cohorts of children with Kawasaki disease and myocarditis | PLOS ONE

Kawasaki Disease Project
Kawasaki Disease Project

The up‐to‐date pathophysiology of Kawasaki disease - Hara - 2021 - Clinical  & Translational Immunology - Wiley Online Library
The up‐to‐date pathophysiology of Kawasaki disease - Hara - 2021 - Clinical & Translational Immunology - Wiley Online Library

Efficacy of primary treatment with immunoglobulin plus ciclosporin for  prevention of coronary artery abnormalities in patients with Kawasaki  disease predicted to be at increased risk of non-response to intravenous  immunoglobulin (KAICA): a
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a